Skip to main content

Table 1 Molecular characteristics of Ig H and IgL rearrangements in CLL mAbs used in these studies

From: Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation

CLL No.a

Subse†b

IGHV

Mut.c status

%d Mut.

IGHD

IGHJ

HCDR3 amino acid sequencee

IGHf GenBank

IGLV

IGLJ

%d Mut.

LCDR3 amino acid sequencee

IGLf GenBank

068

6

1–69

U-CLL

0.0

3–16

3

ARGGDYDYVWGSYRSNDAFDI

AY553640

K3-20

KJ4

0.0

QQYGSSP_T

AY574935

258

6

1–69

U-CLL

0.0

3–16

3

ARGGIYDYVWGSYRPNDAFDI

AY055485

K3-20

KJ1

0.0

QQYGSSPGT

AY574938

014

9

1–69

U-CLL

0.0

3–03

6

ATKNDFWSGYYEGYYYYYYMDV

AF021951

L3-01

LJ1

0.0

QAWDSSTCYV

AY043106

246

9

1–69

U-CLL

0.3

3–03

6

ARSDQNY_DFWSGYFRYYGMDV

FJ039781

K3-20

KJ1

0.0

QQYGSSPET

FJ039795

355

9

1–69

U-CLL

0.0

3–03

6

ARADLPYYDFWSGMY_YYGMDV

FJ039784

Kl-05

KJ1

0.0

QQYNSY_QT

AJ697904

358

NA

1–69

M-CLL

6.8

1–26

5

AVLPSPLVGATQIWGDY

FJ039785

K3-20

KJ1

4.5

QQYGSSPPT

AJ697906

154

1

1–18

M-CLL

2.4

6–19

4

AREQWLVLSHFDY

AF022009

K1D-39

KJ1

0.0

QQSYSTPPWT

AY043164

340

1

1–02

U-CLL

0.3

6–19

4

AREQWLVLKNFDY

AY553645

K1D-39

KJ2

0.3

QQSYSTPPYT

AY574943

360

1

1–03

U-CLL

0.3

6–19

4

AREQWLVLNYFDY

AY553647

K1D-39

KJ2

0.0

QQSYSPPPYT

AY574945

270

1

1–02

U-CLL

0.0

5–12

4

ARVQWLGLRHFDY

AY055487

K1D-39

KJ2

0.0

QQSYSTPPYT

AY574940

D013

28

1–02

U-CLL

0.0

1–26

6

ARQFSGSPTRYYYYYGMDV

FJ039793

K4-01

KJ4

0.0

QQYYSTPQT

FJ039803

376

NA

1–24

U-CLL

0.0

4–17

1

ATSAFTVTHAEYFQH

FJ039787

K3-11

KJ1

0.3

QQRSNWPWT

FJ039798

415

NA

1–03

U-CLL

0.0

3–10

4

ARRPESGYSFVTPFDY

FJ039788

K1D-39

KJ2

0.0

QQSYSTPPHT

FJ039799

366

9

3–21

U-CLL

0.0

3–03

6

ARGVLNY_DFWSVYY_YYGMDV

FJ039786

K4-01

KJ4

0.0

QQYYSTPLT

FJ039797

282

2

3–21

M-CLL

2.4

1–26

6

ARDANGMDV

AY553643

L3-21

LJ3

1.0

QVWDSSSDHPWV

AY574941

412

2

3–21

M-CLL

2.0

ND

6

ARDQNGMDV

AY553648

L3-21

LJ3

0.7

QVWDSSSDHPWV

AY574946

562

NA

3–21

U-CLL

1.7

6–19

5

VRDEITVAATRPCP

FJ039789

L3-21

LJ3

1.4

QVWDSSDDHPWV

FJ039805

169

NA

3–33

M-CLL

8.8

3–10

4

ARE JJVTGQGGF DY

AY055480

K4-01

KJ4

0.0

QQYYSTPLT

FJ039794

141

NA

4–34

U-CLL

0.0

2–02

5

ARGDWRIVVVPAAVDTAMAANWFDP

AF022005

Kl-27

KJ2

0.3

QKYNSAPRMYT

AY043160

D08

NA

4–34

U-CLL

0.0

6–13

4

ARGGRAAAGKGLLDY

FJ039792

K3-20

KJ1

0.0

QQYGSSPPRT

FJ039802

183

4

4–34

M-CLL

3.1

5–18

6

ARGYGDTPTIRRYYYYGMDV

AF021948

K2-30

KJ2

1.7

MQGTHWPPYT

AY043097

240

4

4–34

M-CLL

3.1

5–18

6

ARGYADTPVFRRYYYYGMDV

AY553641

K2-30

KJ2

2.3

MQGTHWPPYT

AY574937

342

4

4–34

M-CLL

2.7

5–18

6

ARGWGDTPMLKRYYYYGLDV

AY553646

K2-30

KJ2

2.3

MQGTHWPPYT

AY574944

114

8

4–39

U-CLL

0.7

6–13

5

ARRFGYSSSWY_GLDWFDP

AY268372

K1D-39

KJ1

0.7

QQSYSTPRT

AY043094

657

8

4–39

U-CLL

0.3

6–13

5

ASKTGYSSSWY_GRDWFDP

FJ039790

K1D-39

KJ1

0.0

QQSYSTPRT

FJ039800

845

8

4–39

U-CLL

0.0

6–13

5

ASSTGYSSSWYSPTNWFDP

FJ039791

K1D-39

KJ4

0.0

QQSYSTPRT

FJ039801

260

NA

4–b

U-CLL

0.0

2–02

6

ARAEIVWPAAYYYYYGMDV

FJ039783

Kl-27

JK3

0.0

QKYNSAPQVT

FJ039796

255

NA

4–59

M-CLL

4.2

3–22

4

ARHRGYESSGYYSSYFDY

FJ039782

L3-01

LJ1

2.2

QAWDSSTW

FJ039804

  1. aCLL number (No.).
  2. bNA: Not attributable to a currently defined stereotypic subset (25,26).
  3. cMutation (Mut.) status of IGHV: unmutated (U-CLL) or mutated (M-CLL).
  4. dPercent mutation of IGHV or IGLV as compared with germline according to IMGT (54).
  5. eHCDR3 or LCDR3 amino acid sequences according to IMGT with bold characters indicating non-identical residues among members of the same subset (excluding CLL 014).
  6. fGenBank accession numbers for IGH and IGL nucleotide sequences.